Longbow takes stake in tissue regen firm
This article was originally published in Clinica
UK tissue regeneration products developer BioCeramic Therapeutics (BCT) today announced it has closed a £1.2m financing round, which was led by new investor Longbow Capital. The latter invested £400,000, with Imperial Innovations contributing £300,000 and other existing shareholders making up the remainder of the funds. The new capital will be used by London-based BCT to prepare for the commercialisation of its first products, which include bone graft substitutes, in 2010. The financing follows the election of Dr Stephan Rietiker to the post of chairman (www.clinica.co.uk, October 19 2009).
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.